Refractory Multiple Myeloma clinical trials

Explore recruiting refractory multiple myeloma clinical trials.

Recruiting refractory multiple myeloma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Refractory Multiple Myeloma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2 Study of Etentamig in Combination with a CELMoD Agent for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

France, Norway, Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Venetoclax and Dexamethasone in translocation (11;14) positive relapsed and refractory multiple myeloma (VICTORIA)

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma

Sweden

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma (DREAMM 8)

Czechia, Greece, Germany, Poland, France, Italy +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2

Italy, Austria, Germany, Hungary, Spain, Norway +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

ISKPD-IFM2018-03-Multicenter Open label Phase 2 study of Isatuximab plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Refractory Multiple Myeloma trials by city

Refractory Multiple Myeloma in Toronto Refractory Multiple Myeloma in Vancouver Refractory Multiple Myeloma in Montreal Refractory Multiple Myeloma in Calgary Refractory Multiple Myeloma in Edmonton Refractory Multiple Myeloma in Ottawa Refractory Multiple Myeloma in Winnipeg Refractory Multiple Myeloma in Quebec City Refractory Multiple Myeloma in Hamilton Refractory Multiple Myeloma in Kitchener Refractory Multiple Myeloma in London Refractory Multiple Myeloma in Halifax Refractory Multiple Myeloma in New York Refractory Multiple Myeloma in Los Angeles Refractory Multiple Myeloma in Chicago Refractory Multiple Myeloma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease